drugset / Trial / NCT06990087
T-cell Therapy in Patients With PML
NaSingle-groupOpen-labelTreatment
Summary
There is no approved standard treatment für progressive multifocal leukoencephalopathy (PML). The sponsor of the study is developing a new treatment. For this reason, the investigational medicinal product (IMP) called 'human allogenic HPyV-2-specific T cells' is to be tested in this study. The sponsor wants to find out whether the IMP is safe, influences the neurological status and improves the quality of the life of patients . It is to be investigated whether the IMP can be used to treat the disease and whether it could have an advantage over the standard therapy in terms of survival rate.
Timeline
- Start
- 2026-02-06
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human allogenic HPyV-2-specific T cells | Cell therapy | 10000 cells/kg | Intravenous |
| Subject | human allogenic HPyV-2-specific T cells | Cell therapy | 20000 cells/kg | Intravenous |